Loading
Viral Infections and Immunology Research / Eosinophilic Disorders and Syndromes · Journal article
Ep Europace · August 1, 2026
A consensus or society position rather than new primary data.
This is an international multisociety consensus statement providing structured clinical guidance for diagnosis, treatment, and follow-up of arrhythmias in myocarditis and inflammatory cardiomyopathy. It organizes recommendations using a disease phase framework (hot, hot-to-cold, and cold phases) and stratifies management by inflammation status, combining antiarrhythmic therapy with disease-targeted treatment during active inflammation and substrate-based strategies in later stages.
Journal article. Patients with myocarditis and inflammatory cardiomyopathy across disease phases (hot, hot-to-cold, cold).
Myocarditis is identified as an important and frequently underrecognized cause of atrioventricular conduction disease and ventricular arrhythmias Arrhythmic risk evolves over time through interplay of myocardial inflammation, fibrosis, and genetic predisposition Hot-to-cold transition is emphasized as an arrhythmogenic window requiring particular attention
Later-stage management includes substrate-based strategies: pharmacological therapy, device implantation, or ablation
Clinicians managing arrhythmias in myocarditis should adopt phase-aware risk stratification and tailor antiarrhythmic and device strategies to the inflammatory stage. This consensus framework integrates genetic background and disease dynamics to guide diagnostic and therapeutic decision-making.
This is a structured international consensus statement providing clinical recommendations for arrhythmia management in myocarditis and inflammatory cardiomyopathy across disease phases, graded by evidence quality and author consensus.
As stated by the source record.
Clinicians managing arrhythmias in myocarditis should adopt phase-aware risk stratification and tailor antiarrhythmic and device strategies to the inflammatory stage. This consensus framework integrates genetic background and disease dynamics to guide diagnostic and therapeutic decision-making.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Myocarditis is an important and frequently underrecognized cause of atrioventricular conduction disease and ventricular arrhythmias and may also be associated with atrial arrhythmias and sinus node dysfunction. Arrhythmic risk evolves over time as a result of the interplay between myocardial inflammation, fibrosis, and genetic predisposition. Despite its clinical relevance, guidance for the diagnosis, treatment, and follow-up of arrhythmias in myocarditis has remained limited. This consensus statement provides a structured framework for the management of arrhythmias in myocarditis and inflammatory cardiomyopathy (Infl-CMP), integrating disease phase and genetic background into clinical decision-making. It offers practical guidance across the disease spectrum, including diagnostic evaluation, therapeutic strategies, and longitudinal follow-up. The document was jointly developed by the European Heart Rhythm Association of the European Society of Cardiology (ESC) in collaboration with the Heart Failure Association of the ESC, the ESC Working Group on Myocardial & Pericardial Diseases, and the European Association of Preventive Cardiology of the ESC, together with the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society. Consensus advice is organized using a phase-aware framework distinguishing hot, hot-to-cold, and cold phases, with clinical consensus statements graded according to opinion-, observational-, or randomized trial-based evidence and supported by formal author voting. Arrhythmia management is stratified by disease phase. During active inflammation, antiarrhythmic therapy is combined with aetiology-targeted treatment or immunosuppression when indicated. In later stages, substrate-based strategies include pharmacological therapy, device implantation, or ablation. Emphasis is placed on hot-to-cold transition as an arrhythmogenic window and on risk stratification.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.